Loading…
Shanghai preclinical CRO providing drug-safety and toxicology testing services to Chinese and global pharma developers.
Shanghai preclinical CRO providing drug-safety and toxicology testing services to Chinese and global pharma developers.
Is paid per study by drug developers who need toxicology and safety testing before human trials, so revenue follows the number and size of studies it wins, and long-running programmes bring repeat work from the same clients. Laboratories certified to good laboratory practice, the standard regulators require, are its core assets.
In one line: A small Chinese Charles River Labs (toxicology arm).
Moat: narrow (regulatory licence, installed base). GLP-certified lab facilities and accumulated regulatory track record are slow for new entrants to replicate.
Headquarters: Shanghai, China · Employees: 1,173
Size Shanghai InnoStar Bio-tech (688710.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.17B, the 2012th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥86.00 on 6 Nov 2026.
Performance Over six months the shares gained 28.4%, against -10.5% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 23.8% over the last twelve months (peer median -1.2%); the operating margin is 6.4% (peer median 10.6%).
Valuation It trades at 85.2× forward earnings against a peer median of 19.6× (2nd most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 6 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.03B | CN¥811M | CN¥1.14B | CN¥1.04B | CN¥863M |
| Revenue growth | — | -29% | +10% | +20% | — |
| Gross profit | CN¥377M | CN¥193M | CN¥368M | CN¥438M | CN¥333M |
| EBITDA | n/a | CN¥40.7M | CN¥211M | CN¥269M | CN¥186M |
| Net income | CN¥78.3M | -CN¥30.5M | CN¥148M | CN¥194M | CN¥135M |
| Free cash flow | CN¥207M | -CN¥32.6M | -CN¥384M | -CN¥65.8M | CN¥133M |
| Capital expenditure | CN¥179M | CN¥134M | CN¥288M | CN¥234M | CN¥146M |
| Total debt | CN¥122M | CN¥116M | CN¥236M | CN¥255M | CN¥248M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai InnoStar Bio-tech 688710.SS | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 26.6× | 25.3% |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
| Joinn Laboratories (China) 603127.SS | $4.58B | +15% | +12% | -4% | 40.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688710.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.8% | -2.2% | 3rd lowest of 21 |
| 6-month return | +28.4% | -10.5% | 3rd highest of 21 |
| Distance from 52-week high | -23.2% | -31.2% | 9th highest of 21 |
| Revenue growth (TTM) | +23.8% | -1.2% | 6th highest of 19 |
| Operating margin | 6.4% | 10.6% | 10th lowest of 20 |
| Forward P/E | 85.2× | 19.6× | 2nd most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 16.2% | 3.3% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +19.4% | +6.1% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -3.3 pp | -0.4 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | +3.8 pp | -0.2 pp | 6th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |